← Back to all trials
Not Yet Recruiting
NCT05638438
Efficacy and Safety of Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC: A Retrospective Real-world Study
Conditions: Hepatocellular Carcinoma Non-resectable
Sex: All
Ages: 18 Years – 75 Years
Enrollment: 100
Sponsor: Zhujiang Hospital
Summary
This Retrospective Real-world study was designed to evaluate the clinical efficacy and safety of the Combination of transarterial therapies with donafenib plus Anti-PD-1 Antibody for Unresectable Hepatocellular Carcinoma.
Eligibility Criteria
Inclusion Criteria:clinically or histopathologically diagnosed HCC;not suitable for curative surgery, or local ablation;age 18~75 years；Barcelona Clinic Liver Cancer (BCLC) Stage-B or C HCC; 5) Child-Pugh score A or B7; 6) Eastern Cooperative Group (ECOG) performance status ≤1.;7）no serious heart, lung, or renal dysfunction； 8）at least 1 measurable lesion according to modified Response Evaluation Criteria in Solid Tumors (mRECIST)Exclusion Criteria:1）comorbidity with other severe systemic diseases; 2）life expectancy is less than 3 months; 3) discontinuation of treatment for personal reasons or inability to tolerate; 4）incomplete data.-
Source: ClinicalTrials.gov (NCT05638438). StuddyBuddy aggregates publicly available trial information.
